Skip to main content

Drug treatment made in Houston to combat Rett syndrome clears FDA hurdle

Published Jan 26, 2023 by A.J. Mistretta

genetic.JPG

A promising new drug intended to treat a debilitating neurological disease impacting children is being manufactured here in Houston and now has FDA investigational clearance. It’s another indication of the region’s expanding life sciences research and manufacturing infrastructure. 

Clinical stage drug company Neurogene Inc., said this week that the FDA has approved its application for NGN-401 to treat Rett syndrome, a progressive neurological disorder that affects 1 in every 10,000 female babies. The syndrome is caused by a gene mutation that can affect the brain and nervous system during early development, prompting rapid regression in speech, fine motor skills and other symptoms after 18 months. There are currently no disease-modifying therapies for Rett syndrome, leaving doctors to simply manage symptoms. 

Neurogene’s NGN-401 is a gene therapy investigational product that is the first to deliver the full-length human MECP2 gene, the specific gene that is mutated in those diagnosed with Rett’s syndrome. The treatment uses the company’s proprietary EXACT gene regulation technology that can deliver a desired level of transgene expression within a narrow range that’s critical in treating Rett syndrome to avoid toxic side effects. NGN-401 has undergone extensive preclinical study and demonstrated strong efficacy, according to the company. The treatment is being made at Neurogene’s GMP manufacturing facility in southwest Houston. 

“We believe the preclinical profile for NGN-401 is highly compelling, with the strongest results generated to date across multiple animal models,” said Rachel McMinn, Ph.D., CEO and Founder of Neurogene. “FDA clearance of NGN-401 represents a significant milestone for Neurogene and the Rett syndrome community and underscores our commitment to turn devastating neurological diseases into treatable conditions, and to improve the lives of patients and families impacted by these rare diseases.”

“Rett syndrome is a debilitating disease with a devastating impact on children and their families, with no disease-modifying treatments available,” said Dr. Bernhard Suter, Assistant Professor of Pediatrics and Neurology at Baylor College of Medicine and neurologist at Texas Children’s Hospital. “The upcoming clinical study of NGN-401, which has a mechanism of action aimed at addressing the root cause of disease, offers hope for improving the lives of those suffering from Rett syndrome.”

A 2022 study commissioned by the Greater Houston Partnership and developed by Newmark Consulting Group identified Houston’s industry-leading expertise in cell and gene therapy, biologic drug development, and molecular diagnostics as strong opportunities for life sciences growth in this region. 

Houston ranks second in the nation in clinical trial volume, with more than 4,600 currently active clinical trials, representing 15% of all active U.S. trials. Houston-area institutions received $864.1 million in National Institutes of Health (NIH) grant funding, up 16.3% from 2020. In the last five years, the region received nearly $3.9 billion in NIH funding, an average of $740.7 million per year. Supported by the world-class institutions that comprise the Texas Medical Center and Houston’s sizeable patient population, the Newmark study found that expansive opportunities exist for commercial synergies with leading healthcare providers in the region. 

Learn more about the life sciences sector in Houston

Related News

Economic Development

Houston Region Asserts Biotech Excellence at BIO International Convention

6/25/25
The Greater Houston Partnership and regional partners showcased Houston’s thriving life sciences and biotechnology ecosystem at the 2025 BIO International Convention in Boston. As the premier annual biotechnology conference in the United States, BIO 2025 drew nearly 20,000 global attendees, offering a powerful platform to highlight the region’s momentum, innovation, and growing opportunities in the sector.    BioHouston, Galveston EDP, Partnership Lake Houston, Pearland EDC, the Sugar Land Office of Economic Development and Tourism and The Woodlands EDP presented the many assets and unique benefits the region offers to biotechnology companies from startup to full-scale, including 8 million square feet of life sciences space, strategic workforce and educational initiatives, as well as an overall favorable approach to incentives and permitting.    "Working alongside the different members of our region and telling the story of the amazing product that Greater Houston has to offer is invigorating," Galveston EDP Executive Director Joshua Owens said. "Being able to showcase our ecosystem to a worldwide audience is an exceptional step toward creating opportunities for the people of Houston."    Recent wins, such as Bionova Scientific's move to The Woodlands and United Therapeutics’ move to Generation Park, serve as testaments to the variety of options for life science businesses in our region. With pronounced capabilities in research and development, manufacturing and innovation, life sciences companies of all kinds can find a welcoming home in the Houston region.    To learn more about our life sciences and biotechnology ecosystem, visit our life sciences page. 
Read More
Life Sciences

From Setback to Strategy: How San Jacinto College and Generation Park are Building Houston’s Biotech Workforce

4/28/25
Like every city, Houston experiences setbacks. The difference is Houston doesn’t dwell on them. It adapts, rebuilds and always comes back stronger. That’s exactly what the region is doing with biotech, an emerging sector where Houston is determined to lead.  The region’s economic development strategy shifted after losing Amazon’s HQ2 in 2019. Leaders doubled down on partnerships, long-term planning and industry diversification.  In 2022, there was another missed opportunity. A leading pharmaceutical company’s decision to choose North Carolina highlighted another critical gap in Houston – the need for a biotech workforce.   Rather than retreat, Houston responded with action. San Jacinto College (SJC) and Generation Park launched a bold partnership to build a biotech talent pipeline, ensuring the region is ready for the next big opportunity.  Learn more about Houston’s life sciences industry and how local colleges and businesses are working together to build the region’s biotech workforce.  SJC & Generation Park Partnership  Ryan McCord, McCord Development President and the visionary behind Generation Park, had long believed Houston could lead in life sciences. But as biotech investments flowed to other cities, it became clear: infrastructure alone wasn’t enough.  While Houston’s life sciences sector has grown steadily over the past decade— recording the second-highest employment growth rate among major markets from 2022 to 2023, according to CBRE’s 2025 Life Sciences Outlook—the region continued to face a shortage of technicians to support critical functions such as laboratory setup, data collection and research observation.  That’s when McCord turned to SJC, a proven leader in workforce development with a track record of building industry-aligned programs. Together, they launched the Center for Biotechnology, a workforce-first solution to close the talent gap and make Houston a top destination for biotech companies.  "San Jacinto College’s Biotechnology Center at Generation Park is the catalyst our region needs to fill the gap in our existing life science ecosystem and accelerate biomanufacturing in Houston,” said McCord in a news release.  Inside the Center for Biotechnology  Opening this summer, the Center for Biotechnology offers more than just textbook knowledge, it delivers hands-on training with industry-grade equipment. At its core is a pilot-scale bioprocessing plant where students will gain real-world experience using the same tools found in commercial facilities.   Click to expand To develop the curriculum, SJC partnered with the National Institute for Bioprocessing Research and Training (NIBRT), a global leader in biopharma education. That partnership makes the center the exclusive provider of NIBRT-licensed training in the southern U.S., and one of just six institutions worldwide with this distinction.  “Building on San Jacinto College’s established track record of working with industry to develop need-specific training and accreditation centers, the partnership with NIBRT represents an opportunity to train the workforce that Houston's biopharma industry needs to sustain its rapid growth,” said Brenda Hellyer, Chancellor of SJC, in a statement. “We also expect to contribute to the global market by training people eager to enter this growing industry from around the United States and beyond.”  The center also offers students exposure to emerging fields like cell and gene therapy. A regional advisory board of life sciences leaders will guide the curriculum to ensure it evolves with industry needs.  Strategic Location  The center is located within Generation Park, one of Houston’s fastest-growing innovation districts, and sits just steps away from BioHub Two, a 45-acre biomanufacturing campus currently under development. Once complete, BioHub Two will feature 500,000 square feet of state-of-the-art lab, office and cGMP manufacturing space, designed to attract life sciences companies to the region.   Click to expand What makes this proximity so powerful is the built-in connection between workforce development and industry growth. Companies moving into BioHub Two won’t just gain access to premier infrastructure, they’ll have a direct pipeline to trained, job-ready talent.  Spanning 4,300 acres, Generation Park is also home to leading institutions like Lone Star College and companies such as TechnipFMC and Apache Industrial Services. Beyond businesses, the district offers a great quality of life, surrounded by restaurants, shops, green space and residential options, all just a short drive from George Bush Intercontinental Airport and Port Houston.  Positioned for the Future  The partnership between SJC and Generation Park is more than a response to a missed opportunity – it’s a bold investment in Houston’s future. The Center for Biotechnology demonstrates how aligning education with industry needs can unlock long-term growth, strengthen the region’s talent pipeline, and position Houston as a national hub for life sciences innovation and biomanufacturing. 
Read More

Related Events

Executive Partners